A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages()

OBJECTIVES: Interleukin (IL)-6 inhibitors are administered to treat patients hospitalized with COVID-19. In 2021, due to shortages, different dosing regimens of tocilizumab, and a switch to sarilumab, were consecutively implemented. Using real-world data, we compare the effectiveness of these IL-6 i...

Descripción completa

Detalles Bibliográficos
Autores principales: Swets, Maaike C., Moss, Rob J., Kor, Flip, Hilarius, Doranne, Moes, Dirk Jan A.R., Berkhout, Willemijn EM, van den Toorn, Leon M., van den Oever, Niels C. Gritters, de Valk, Renee, Rosendaal, Frits R., Hunfeld, Nicole, Groeneveld, Geert H., de Boer, Mark G.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893803/
https://www.ncbi.nlm.nih.gov/pubmed/36738957
http://dx.doi.org/10.1016/j.ijid.2023.01.041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893803/
https://www.ncbi.nlm.nih.gov/pubmed/36738957
http://dx.doi.org/10.1016/j.ijid.2023.01.041

Ejemplares similares